CLINICAL TRIALS PROFILE FOR HEMLIBRA

All Clinical Trials for HEMLIBRA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02622321 ↗	A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors	Completed	Chugai Pharmaceutical	Phase 3	2015-11-18	This multicenter, open-label study will evaluate the safety, efficacy and pharmacokinetics of prophylactic emicizumab treatment in participants previously treated with episodic or prophylactic bypassing agents. Episodic bypassing agent participants will be randomized in a 2:1 fashion to receive emicizumab prophylaxis (Arm A) versus no prophylaxis (Arm B) and will be stratified across Arms A and B according to the number of bleeds they experienced over the last 24 weeks prior to study entry (less than [/=] 9 bleeds); Arm B participants will have the opportunity to switch to emicizumab prophylaxis after at least 24 weeks on-study. Prophylactic bypassing agent participants will switch to emicizumab prophylaxis (Arm C) from the start of the trial; enrollment will be extended for 24 weeks after the last participant has enrolled in Arms A or B or until approximately 50 participants have enrolled in Arm C, whichever occurs first. Episodic bypassing agent participants who previously participated in the non-interventional study BH29768 (NCT02476942) who were unable to enroll in Arms A or B, or participants on prophylactic bypassing agents who were unable to enroll in Arm C, prior to their closure will have the opportunity to enroll in Arm D. Like participants in Arms A and C, Arm D participants will receive emicizumab prophylaxis from the start of the trial. All participants will continue to receive episodic bypassing agent therapy to treat breakthrough bleeds, preferably with recombinant activated factor VII (rFVIIa).
NCT02622321 ↗	A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors	Completed	Hoffmann-La Roche	Phase 3	2015-11-18	This multicenter, open-label study will evaluate the safety, efficacy and pharmacokinetics of prophylactic emicizumab treatment in participants previously treated with episodic or prophylactic bypassing agents. Episodic bypassing agent participants will be randomized in a 2:1 fashion to receive emicizumab prophylaxis (Arm A) versus no prophylaxis (Arm B) and will be stratified across Arms A and B according to the number of bleeds they experienced over the last 24 weeks prior to study entry (less than [/=] 9 bleeds); Arm B participants will have the opportunity to switch to emicizumab prophylaxis after at least 24 weeks on-study. Prophylactic bypassing agent participants will switch to emicizumab prophylaxis (Arm C) from the start of the trial; enrollment will be extended for 24 weeks after the last participant has enrolled in Arms A or B or until approximately 50 participants have enrolled in Arm C, whichever occurs first. Episodic bypassing agent participants who previously participated in the non-interventional study BH29768 (NCT02476942) who were unable to enroll in Arms A or B, or participants on prophylactic bypassing agents who were unable to enroll in Arm C, prior to their closure will have the opportunity to enroll in Arm D. Like participants in Arms A and C, Arm D participants will receive emicizumab prophylaxis from the start of the trial. All participants will continue to receive episodic bypassing agent therapy to treat breakthrough bleeds, preferably with recombinant activated factor VII (rFVIIa).
NCT02795767 ↗	A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors	Completed	Chugai Pharmaceutical	Phase 3	2016-07-22	This non-randomized, multicenter, open-label, Phase III clinical study will evaluate the efficacy, safety, and pharmacokinetics of emicizumab administered subcutaneously initially once weekly (QW) in pediatric participants with hemophilia A with FVIII inhibitors. This study will open two additional non-randomized cohorts to investigate once every 2 weeks (Q2W) and once every 4 weeks (Q4W) regimens in pediatric participants.
NCT02795767 ↗	A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors	Completed	Hoffmann-La Roche	Phase 3	2016-07-22	This non-randomized, multicenter, open-label, Phase III clinical study will evaluate the efficacy, safety, and pharmacokinetics of emicizumab administered subcutaneously initially once weekly (QW) in pediatric participants with hemophilia A with FVIII inhibitors. This study will open two additional non-randomized cohorts to investigate once every 2 weeks (Q2W) and once every 4 weeks (Q4W) regimens in pediatric participants.
NCT02847637 ↗	A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors	Active, not recruiting	Chugai Pharmaceutical	Phase 3	2016-09-27	This is a randomized, global, multicenter, open-label, Phase 3 clinical study in participants with severe hemophilia A without inhibitors against Factor VIII (FVIII) who are 12 years or older. The study evaluates two prophylactic emicizumab regimens versus no prophylaxis in this population with emphasis on efficacy, safety, and pharmacokinetics.
NCT02847637 ↗	A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors	Active, not recruiting	Hoffmann-La Roche	Phase 3	2016-09-27	This is a randomized, global, multicenter, open-label, Phase 3 clinical study in participants with severe hemophilia A without inhibitors against Factor VIII (FVIII) who are 12 years or older. The study evaluates two prophylactic emicizumab regimens versus no prophylaxis in this population with emphasis on efficacy, safety, and pharmacokinetics.

Clinical Trial Conditions for HEMLIBRA

Condition Name

Condition Name for HEMLIBRA
Intervention	Trials
Hemophilia A	9
Hemophilia A With Inhibitor	3
Severe Hemophilia A	2
Moderate Hemophilia A	1

Condition MeSH

Condition MeSH for HEMLIBRA
Intervention	Trials
Hemophilia A	16
Deficiency Diseases	1
Von Willebrand Diseases	1
Von Willebrand Disease, Type 3	1

Clinical Trial Locations for HEMLIBRA

Trials by Country

Trials by Country for HEMLIBRA
Location	Trials
United States	70
Italy	19
Australia	13
Spain	8
Germany	7

Trials by US State

Trials by US State for HEMLIBRA
Location	Trials
California	10
Michigan	7
Indiana	6
Georgia	5
Washington	5

Clinical Trial Progress for HEMLIBRA

Clinical Trial Phase

Clinical Trial Phase for HEMLIBRA
Clinical Trial Phase	Trials
PHASE4	1
Phase 4	5
Phase 3	11

Clinical Trial Status

Clinical Trial Status for HEMLIBRA
Clinical Trial Phase	Trials
Recruiting	7
Active, not recruiting	5
Completed	3

Clinical Trial Sponsors for HEMLIBRA

Sponsor Name

Sponsor Name for HEMLIBRA
Sponsor	Trials
Hoffmann-La Roche	9
Chugai Pharmaceutical	4
Genentech, Inc.	4

Sponsor Type

Sponsor Type for HEMLIBRA
Sponsor	Trials
Industry	19
Other	9
U.S. Fed	2

Hemlibra (emicizumab-kxwh) clinical trials update, market analysis, and exclusivity-driven projection

Last updated: May 21, 2026

Hemlibra (emicizumab-kxwh, Roche/Genentech) remains the dominant prophylaxis therapy for hemophilia A with inhibitors in the US and key ex-US markets. The commercial outlook is driven by (1) sustained payer and provider adoption for bleed prevention, (2) expanding labeled populations across age and dosing regimens, and (3) portfolio durability created by biologic exclusivity and a dense patents-and-life-cycle strategy, with biosimilar entrants constrained by clinical interchangeability and manufacturing complexity.

What is Hemlibra (emicizumab-kxwh) and what indications drive demand?

Executive answer: Hemlibra is a prophylactic bispecific antibody for congenital hemophilia A that targets activated factor IX and factor X to restore hemostasis bypassing factor VIII.

Hemophilia A with inhibitors: the core revenue engine

Hemlibra’s largest addressable segment is people with hemophilia A who have factor VIII inhibitors. This segment supports high persistence because the therapy replaces otherwise recurring on-demand inhibitor bypassing approaches and reduces bleed burden over time.

Expanding labeled populations: prophylaxis in broader hemophilia A groups

Hemlibra has expanded beyond inhibitor status to prophylaxis across additional hemophilia A populations, including certain groups without inhibitors, depending on country label. Uptake in these groups typically ramps more slowly than inhibitors due to earlier treatment paradigms and payer scrutiny around long-term biologic cost versus standard prophylaxis.

Dosing and administration pattern matters for adoption

Hemlibra is commonly administered subcutaneously with scheduled dosing. In-market preference typically favors regimens that reduce clinic burden and support home administration, improving adherence and persistence.

---

What are the latest clinical trial updates for Hemlibra (emicizumab) in hemophilia A?

Executive answer: Recent trial activity is centered on extending prophylaxis into additional age groups and refining dosing strategies, while continuing real-world-aligned outcomes such as annualized bleeding rate (ABR), joint health, factor consumption, safety, and immunogenicity.

Trial update themes that typically move label and reimbursement

1. Longer follow-up for safety and efficacy durability
   Hemlibra’s profile depends on long-term outcomes, including thrombotic microangiopathy and inhibitor-related safety signals historically associated with factor bypassing therapy combinations.
2. Population expansion and pediatric execution
   Pediatric programs focus on growth-period PK/PD consistency, bleed prevention targets, caregiver usability, and immunogenicity.
3. Dosing optimization
   Studies that simplify loading and maintenance schedules can shift cost-of-care and adherence, supporting payer acceptance.

What outcomes are being used as primary endpoints

Featured endpoints in Hemlibra programs include:

• ABR on prophylaxis
• proportion of participants with zero bleeds
• efficacy under surgery or perioperative management
• safety events and serious adverse events
• factor VIII inhibitor titers when relevant
• immunogenicity (anti-drug antibodies)

No additional clinical-trial specifics can be produced here without a reliable, current source list for trial phase, enrollment status, and readout dates.

---

How strong is Hemlibra’s patent estate and what patents protect the drug?

Executive answer: Hemlibra’s protection combines biologic exclusivity plus a layered set of patent rights covering composition, antibodies, methods of use, and manufacturing. That combination supports extended market exclusivity against biosimilar entry and reduces generic small-molecule substitution risk.

What categories usually cover the Hemlibra patent stack

Because Hemlibra is a complex biologic, protection typically spans:

• antibody structure and binding characteristics
• compositions and formulations
• dosing regimens and prophylaxis methods
• manufacturing processes and process controls
• combination regimens and management strategies

How patent strength translates into biosimilar timing risk

For biosimilars, timing is driven by:

• biological product exclusivity periods
• patent expiry timing across jurisdictions
• the scope of blocking patents (composition vs method-of-use vs manufacturing)
• litigation outcomes or settlements that delay approval and launch

Patent number-level detail and expiration timelines require a current, citable patent docket or Orange Book/Biologics License Application listing, which is not provided in this prompt.

---

When does Hemlibra lose exclusivity, and what are the likely biosimilar entry scenarios?

Executive answer: Hemlibra’s effective exclusivity horizon is governed by US biologic exclusivity and the relevant patent expiries, which typically extend beyond initial marketing approval. Biosimilar launch scenarios depend on successful litigation defenses and the ability to rely on interchangeability or demonstrate biosimilarity under the totality of evidence standard.

Biosimilar entry scenario structure

1. Hard stop due to blocking patents
   Approval may be possible, but commercialization can be enjoined if court rulings or settlement terms block launch.
2. Delayed launch following patent settlement
   Many biosimilar cases settle with defined launch dates or modified labeling.
3. Launch with narrower scope
   A biosimilar may enter with limited initial indication coverage where evidence supports first.

Exact dates and court/settlement terms are not provided here; producing them would require a specific litigation and regulatory dataset.

---

What is the Orange Book status of Hemlibra?

Executive answer: Hemlibra is a biologic (not a typical small-molecule drug), so it is generally not analyzed through the Orange Book listing framework used for NDAs. Instead, biosimilar and exclusivity status is tracked through the BLA exclusivity framework and the patent listings tied to the biologic application process.

Orange Book listing content is not available in the prompt; providing listing-level detail would be speculative.

---

Which companies are challenging Hemlibra, and what patent litigation affects launch timing?

Executive answer: Competitive pressure for Hemlibra is expected from biosimilar developers and specialty biologics players pursuing abbreviated development pathways and patent challenges. Launch timing is impacted by litigation over blocking patents and by settlement agreements that set an agreed launch date or restrict commercialization.

No named challengers, case numbers, or settlement terms are provided in the prompt; producing a litigation map requires a current case-by-case record.

---

How does Hemlibra compare with other hemophilia A prophylaxis options?

Executive answer: Hemlibra competes against (1) standard factor VIII prophylaxis and (2) other non-factor and gene- and cell-based modalities in hemophilia A. In the inhibitor population, Hemlibra’s value proposition is bleed reduction without relying on factor VIII potency and inhibitor-neutralization strategies.

Comparison dimensions that impact market share

• ABR reduction magnitude versus comparator prophylaxis
• dosing frequency and home use feasibility
• joint health and long-term musculoskeletal outcomes
• cost-of-therapy and payer authorization friction
• safety management compared with factor bypass regimens
• patient eligibility and inhibitor status determination

Where Hemlibra holds strongest differentiation

• hemophilia A with inhibitors where factor VIII replacement is constrained by inhibitor biology
• long-term prophylaxis programs where persistence is a major driver of clinical benefit

---

What formulations and delivery systems are protected by Hemlibra patents?

Executive answer: Hemlibra is delivered via subcutaneous administration in a fixed-concentration biologic format. Patent coverage typically addresses composition, antibody engineering, formulation stability, and administration-supporting preparation.

Formulation-specific patent numbers, excipient composition claims, and container/closure embodiments are not supplied in the prompt.

---

What manufacturing and IP barriers exist for Hemlibra biosimilars?

Executive answer: Biosimilar development faces high barriers from:

• maintaining structural fidelity for a bispecific antibody
• establishing functional similarity for binding and effector activity
• ensuring consistent glycosylation and stability
• scaling a reliable manufacturing process under strict comparability standards
• navigating patent-protected manufacturing methods and process controls

---

Market analysis: Hemlibra revenue exposure and growth drivers

Executive answer: Hemlibra’s market is shaped by high unmet need in inhibitor patients, long treatment persistence, and slow-to-accelerate adoption in broader prophylaxis populations. Growth tends to be driven by:

• treated patient count expansion from diagnostic identification and referral
• persistence and dose optimization strategies
• contracting and payer alignment for long-term prophylaxis
• pediatric uptake and dosing adjustments
• hospital and hemophilia center protocol standardization

Key variables that determine near-to-midterm trajectory

• treated population size across inhibitor and non-inhibitor groups
• annualized bleed reduction outcomes that support payer renewal
• adherence and persistence by dosing schedule
• drug acquisition cost trajectory and rebates
• competitive displacement risk from alternative prophylaxis or disease-modifying options

---

Projection: what is the plausible sales path for Hemlibra over the next 5 to 10 years?

Executive answer: A high-confidence direction is continued growth or stable-to-slow growth in the absence of biosimilar entry, followed by a step-down risk if biosimilars or competing modalities secure meaningful access. The most material downside is any early-than-expected biologic exclusivity/patent resolution allowing biosimilar commercialization.

Projection framework (exclusivity-anchored)

• Base case: sustained adoption and persistence with incremental share gains in broader populations; growth moderated by contracting and price pressure.
• Upside case: faster-than-expected uptake in pediatric and non-inhibitor prophylaxis segments plus favorable center protocols.
• Downside case: early biosimilar launch in key markets or meaningful displacement by alternative prophylaxis or durable therapies with better payer economics.

Numerical sales projections require current-year revenue, unit volumes, and market share data plus a named list of trial and regulatory milestones; none are provided in the prompt, so a quantified forecast cannot be produced here without fabricating inputs.

---

Key takeaways

• Hemlibra’s demand is anchored by hemophilia A patients with inhibitors and reinforced by long-term prophylaxis persistence.
• Clinical development remains focused on label expansion, dosing optimization, and long-term safety and efficacy.
• Market durability is supported by biologic exclusivity and a layered patent estate, which typically delays biosimilar commercialization and increases developer execution risk.
• Competitive and biosimilar entry risk is the dominant variable that could change the sales trajectory; the magnitude and timing depend on specific patent and litigation outcomes.

---

FAQs

1. What endpoints matter most for Hemlibra prophylaxis trial success?
2. How do dosing changes affect Hemlibra persistence and payer renewal?
3. What are the practical barriers to switching patients from factor VIII prophylaxis to Hemlibra?
4. Which countries typically provide faster access to hemophilia prophylaxis biologics like Hemlibra?
5. How do biosimilar development timelines interact with patent settlements for Hemlibra?

---

References (APA)

1. (No sources were provided in the prompt to cite.)